Octreotide

Indications & Dose:

Acromegaly, carcinoid syndrome (associated with metastatic carcinoid tumors), vasoactive intestinal peptide tumors (VIPomas), insulinoma,* HIV-associated secretory diarrhea,cryptosporidiosis in HIV-infected persons control of bleeding esophageal varices, irritable bowel syndrome dumping syndrome 

DOSE

GEP

Tumours, initially 0.05 mg once or twice daily by s.c inj. increasing to 0.2 mg three times daily if necessary.

Carcinoid crises, 0.05 m* g by i.v. inj. diluted with saline and given as a bolus

Pancreatic surgery; 0.1 mg by s.c. inj three times daily for 7 days, starting 1 hour before laporatomy.

Acromegaly; when controlled, established, initially 20 mg by intraglutal inj every 4 weeks for 3 months. Adjust subsequent doses according to levels o f GH or IGF-I and clinical response.

Contraindications:

Liver disease, sickle cell anaemia, malignant or wasting disease. Severe chronic depression, history of thromboembolic disorders

Side Effects:

Cautions:

Precautions:

Gallbladder disease (stones or sludge in 48% of patients treated for 12 mo; in 2% of patients treated for 1 mo); may affect glycemic control in diabetics

Interaction:

Warnings:

Adverse Effects:

Lactations:

Pregnancy category B; breast milk excretion unknown

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

CNS: Dizziness, fatigue, headache, weakness

CV: Bradycardia (21% in acromegalies), conduction abnormalities, dysrhythmias

GI: Abdominal discomfort, constipation, diarrhea, distension, flatulence, nausea, pancreatitis, vomiting

HEME: Vitamin B12 deficiency

METAB: Goiter, hyperglycemia, hypoglycemia,hypothyroidism

MS: Bellspalsy leg cramps

SKIN: Alopecia

MISC: Local pain on inj

Patient And Carer Advice: